Literature DB >> 11337099

Corticotropin-releasing hormone in depression and post-traumatic stress disorder.

J W Kasckow1, D Baker, T D Geracioti.   

Abstract

Corticotropin-releasing hormone (CRH) has been implicated in the regulation of a wide range of behaviors including arousal, motor function, feeding, and reproduction. Because depressed patients are often hypercortisolemic and intracerebroventricular administration of CRH to experimental animals produces a syndrome reminiscent of depression, dysregulation of this compound has been suggested to be involved in the pathogenesis of depressive and anxiety disorders. Studies of cerebrospinal fluid CRH levels and clinical neuroendocrine tests in patients with anxiety and affective disorders have supported this hypothesis. This review discusses these neuroendocrine findings in melancholic and atypical depression as well as post-traumatic stress disorder (PTSD). Overall, the data suggest that melancholic depression is characterized by hyperactive central CRH systems with overactivity of the pituitary-adrenal (HPA) axis. On the other hand, atypical depression is characterized by hypoactive central CRH systems and accompanying underactivity of the hypothalamic-pituitary-adrenal axis. Furthermore, the neuroendocrinology of PTSD appears to be unique, in that patients have hyperactive central CRH systems with underactivity of the pituitary-adrenal axis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337099     DOI: 10.1016/s0196-9781(01)00399-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  47 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

2.  Roles for gamma-aminobutyric acid in the development of the paraventricular nucleus of the hypothalamus.

Authors:  Kristy M McClellan; Matthew S Stratton; Stuart A Tobet
Journal:  J Comp Neurol       Date:  2010-07-15       Impact factor: 3.215

3.  Placental Corticotropin-Releasing Hormone Mediates the Association Between Prenatal Social Support and Postpartum Depression.

Authors:  Jennifer Hahn-Holbrook; Christine Dunkel Schetter; Chander Arora; Calvin J Hobel
Journal:  Clin Psychol Sci       Date:  2013-07-01

Review 4.  Organization of brain somatomotor-sympathetic circuits.

Authors:  Ilan A Kerman
Journal:  Exp Brain Res       Date:  2008-03-28       Impact factor: 1.972

5.  Levels of maternal serum corticotropin-releasing hormone (CRH) at midpregnancy in relation to maternal characteristics.

Authors:  Yumin Chen; Claudia Holzman; Hwan Chung; Patricia Senagore; Nicole M Talge; Theresa Siler-Khodr
Journal:  Psychoneuroendocrinology       Date:  2009-12-16       Impact factor: 4.905

6.  Prepregnancy depressive symptoms and preterm birth in the Black Women's Health Study.

Authors:  Ghasi S Phillips; Lauren A Wise; Janet W Rich-Edwards; Meir J Stampfer; Lynn Rosenberg
Journal:  Ann Epidemiol       Date:  2010-01       Impact factor: 3.797

7.  Stable modifications to the expression of neurohormones in the rat hypothalamus in a model of post-traumatic stress disorder.

Authors:  V I Mironova; E A Rybnikova
Journal:  Neurosci Behav Physiol       Date:  2009-12-11

8.  Effects of corticoliberin on synaptic transmission in rat olfactory cortex slices in a water immersion model of depression.

Authors:  V G Shalyapina; A A Mokrushin; A Kh Khama-Murad; O G Semenova
Journal:  Neurosci Behav Physiol       Date:  2009-07-21

9.  Tianeptine: an antidepressant with memory-protective properties.

Authors:  Phillip R Zoladz; Collin R Park; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

10.  Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent.

Authors:  R N Carter; J M Paterson; U Tworowska; D J Stenvers; J J Mullins; J R Seckl; M C Holmes
Journal:  J Neuroendocrinol       Date:  2009-07-07       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.